The central objective of this research is to define ways in which drugs interfere with cholinergic systems on subcellular, cellular and system levels, using gas chromatography/mass spectrometry in conjunction with both stable and radioactive isotopic labelling to obtain a dynamic assessment of cholinergic processes and the factors controlling them. The dynamics of high affinity choline transport and acetylation, and of acetylcholine storage and release, will be studied in vitro in synaptosomes, guinea pig myenteric plexus, rat brain slices and other model systems, and in vivo in rats. Postsynaptic mechanisms will be studied by ligand binding techniques, and the coupling of cholinergic receptors to cellular responses will be investigated in the same tissues by measuring changes in phosphatidylinositol turnover in response to muscarinic agonists, partial agonists and antagonists. Compounds to be studied include cholinergic and anticholinergic agents and agents such as choline and physostigmine which are used to promote central cholinergic activity; psychotropic agents such as antidepressants and neuroleptics which commonly have anticholinergic side effects; lithium, which increases acetylcholine turnover and also interferes specifically with phosphatidylinositol metabolism; and a series of chemical probes which we and others have developed to produce specific biochemical lesions in cholinergic systems. These include a group of irreversible muscarinic agonists, irreversible inhibitors of high affinity choline transport, a precursor of a cholinergic false transmitter and a potent inhibitor of vesicular acetylcholine transport. We expect these probes to be valuable in analyzing both presynaptic and postsynaptic regulatory mechanisms, in producing experimental models of pathological states such as Alzheimer's disease, and potentially in the development of new and more specific therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH017691-18
Application #
3374718
Study Section
(DABB)
Project Start
1977-01-01
Project End
1989-12-31
Budget Start
1987-01-01
Budget End
1987-12-31
Support Year
18
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Figueroa, K W; Suga, H; Ehlert, F J (2010) Investigating the interaction of McN-A-343 with the M muscarinic receptor using its nitrogen mustard derivative and ACh mustard. Br J Pharmacol 160:1534-49
Russell, R W; Escobar, M L; Booth, R A et al. (1994) Accelerating behavioral recovery after cortical lesions. II. In vivo evidence for cholinergic involvement. Behav Neural Biol 61:81-92
Escobar, M L; Russell, R W; Booth, R A et al. (1994) Accelerating behavioral recovery after cortical lesions. I. Homotopic implants plus NGF. Behav Neural Biol 61:73-80
Wu, M F; Jenden, D J; Fairchild, M D et al. (1993) Cholinergic mechanisms in startle and prepulse inhibition: effects of the false cholinergic precursor N-aminodeanol. Behav Neurosci 107:306-16
Cho, A K; Hiramatsu, M; Schmitz, D A et al. (1993) A pharmacokinetic study of phenylcyclohexyldiethylamine. An analog of phencyclidine. Drug Metab Dispos 21:125-32
Szymusiak, R; McGinty, D; Fairchild, M D et al. (1993) Sleep-wake disturbances in an animal model of chronic cholinergic insufficiency. Brain Res 629:141-5
Gylys, K H; Mellin, C; Amstutz, R et al. (1992) Characterization of the irreversible inhibition of high-affinity choline transport produced by hemicholinium mustard. J Neurochem 59:1302-8
Nilsson, B M; Vargas, H M; Hacksell, U (1992) Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem 35:3270-9
Scremin, O U; Jenden, D J (1992) Effects of hypoxia on choline exchange among organs. J Neurochem 59:906-14
Russell, R W; Booth, R A; Jenden, D J et al. (1992) Incomplete reversibility of an experimentally induced hypocholinergic state: biochemical and physiological, but not behavioral, recovery. Pharmacol Biochem Behav 41:433-44

Showing the most recent 10 out of 71 publications